Aclaris Therapeutics Announces Formation of New Scientific Advisory Board

Core Insights - Aclaris Therapeutics, Inc. has established a new Scientific Advisory Board (SAB) focused on pulmonology to enhance its development programs for immuno-inflammatory diseases [1][2]. Company Overview - Aclaris Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel product candidates for patients with immuno-inflammatory diseases who currently have limited treatment options [5]. Scientific Advisory Board Members - Dr. Marianne Mann, an expert in pulmonology and drug development with over 30 years of experience, has held significant roles at the FDA and NIH, focusing on respiratory diseases and clinical trial design [3]. - Dr. Zuzana Diamant, a distinguished pulmonologist and clinical pharmacologist, has extensive experience in asthma and chronic obstructive pulmonary disease research, having co-authored over 200 peer-reviewed publications [4]. Strategic Importance - The expertise of the SAB members in regulatory science, clinical development, and translational research is expected to guide Aclaris Therapeutics in advancing its therapeutic programs [2].